Sign in

Ilias Goranitis

@iliasgoranitis.bsky.social
245 followers 139 following 20 posts

Head, Economics of Genomics & Precision Medicine Unit, University of Melbourne | Health Economics Lead, Australian Genomics | Deputy Head, Melbourne Health Economics, Centre for Health Policy #HealthEconomics #Genomics

PostsRepliesMedia
Reposted by Ilias Goranitis
Nature Medicine @natmed.nature.com · 02/12/2025
How can we measure the value of #genomics in #healthcare? How can #HTA, #implementation & data management be adapted to suit the rapidly evolving nature of genomics? For insights, read the Review from Zornitza Stark, Ilias Goranitis & colleagues. www.nature.com/articles/s41591-025-…
nature.com
Determining the value of genomics in healthcare - Nature Medicine
Assessing the value of genomics is key to informing evidence-based policies; this Review outlines how current approaches to health technology assessment, implementation and data management can be adapted to suit the rapidly evolving technology and evidence base.
165
Ilias Goranitis @iliasgoranitis.bsky.social · 27/11/2025
We discuss progress in measuring and valuing genomics, evidentiary and process challenges for HTA and practical solutions for policy decisions-making, implementing genomics to deliver value, life-cycle HTA and learning healthcare, broader macro-economic benefits.
020
Ilias Goranitis @iliasgoranitis.bsky.social · 27/11/2025
In this Nature Medicine paper, we draw from our experiences in evaluating and implementing #genomics in Australia, Canada, England, Hong Kong and the US www.nature.com/articles/s41...
nature.com
Determining the value of genomics in healthcare - Nature Medicine
Assessing the value of genomics is key to informing evidence-based policies; this Review outlines how current approaches to health technology assessment, implementation and data management can be adap...
1107
Reposted by Ilias Goranitis
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 27/11/2025
Determining the value of genomics in healthcare” is now published in Nature Medicine. Led by A/Prof Ilias Goranitis, the paper brings together international co-authors to examine how the value of genomics can be assessed. Read the full article: www.nature.com/articles/s41...
053
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 27/11/2025
www.nature.com/articles/s41... 🔥🔥🔥 Is genomics value for money??? 🧬💰 👉 How do we define it? 👉 Measure it? 👉 And deliver it? rdcu.be/eR243 @iliasgoranitis.bsky.social @stephaniebest.bsky.social @hadleyssmith.bsky.social @rich-genomics.bsky.social @jbuchanan-ox.bsky.social @rdexeter.bsky.social
nature.com
Determining the value of genomics in healthcare - Nature Medicine
Assessing the value of genomics is key to informing evidence-based policies; this Review outlines how current approaches to health technology assessment, implementation and data management can be adap...
0114
Reposted by Ilias Goranitis
GenomeSeb @genomeseb.bsky.social · 09/10/2025
Proud to share our BabyScreen+ #gNBS study is now out in @naturemedicine.bsky.social: 1000 babies screened, results in <2wks, 16 high chance findings, incl. 2 with major impact on care. Big thanks to @zornitza.bsky.social and the study team! www.nature.com/articles/s41...
nature.com
Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study - Nature Medicine
The BabyScreen+ study offered genomic screening to 1,000 newborns in Australia, and showed that the approach is feasible and positively received by families, leading to molecular diagnoses in 1.6% of babies.
032
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 09/10/2025
🤗 Out now @naturemedicine.bsky.social results of our genomic NBS study BabyScreen+ 👶🧬 👉 www.nature.com/articles/s41... 1,000 babies WGS using existing cards 600+ conditions 13 day TAT 16 diagnoses (vs 1 in std NBS) High clinical impact High parental acceptability
02515
Ilias Goranitis @iliasgoranitis.bsky.social · 27/08/2025
The sustainability argument is a strong one in favour of tax-based systems — read our commentary pubmed.ncbi.nlm.nih.gov/26369417/
pubmed.ncbi.nlm.nih.gov
Health care financing and the sustainability of health systems - PubMed
The economic crisis brought an unprecedented attention to the issue of health system sustainability in the developed world. The discussion, however, has been mainly limited to "traditional" issues of ...
010
Ilias Goranitis @iliasgoranitis.bsky.social · 19/07/2025
Help us develop a roadmap for stakeholders to consider when integrating #healtheconomics alongside #genomics to inform decision-making. Please share your local perspectives on challenges & opportunities of evaluating and implementing genomics q.surveys.unimelb.edu.au/jfe/form/SV_...
q.surveys.unimelb.edu.au
Qualtrics Survey | Qualtrics Experience Management
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
121
Ilias Goranitis @iliasgoranitis.bsky.social · 29/05/2025
Wonderful to see our paper on the #Value and #Implementation of #Genomic_Newborn_Screening published in @ajhgnews.bsky.social #BabyScreen+ #HealthEconomics #DCE
032
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 28/05/2025
What does the Australian public think about the value and implementation of genomic NBS? 🧬👶⚖️ @ajhgnews.bsky.social @iliasgoranitis.bsky.social @stephaniebest.bsky.social @genomeseb.bsky.social @genetic-fi.bsky.social #raredisease #genomics #healtheconomics www.sciencedirect.com/science/arti...
sciencedirect.com
Public preferences for the value and implementation of genomic newborn screening: Insights from two discrete choice experiments in Australia
Integrating genomic sequencing into newborn screening (NBS) has transformative potential for the identification and management of genetic conditions. …
1136
Reposted by Ilias Goranitis
Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 10/04/2025
A few weeks ago, @iliasgoranitis.bsky.social presented at the Pan American Health Organisation webinar series. The webinar explored the challenges and opportunities of incorporating genomic innovations into health systems. youtube.com/watch?v=cPQr...
youtube.com
Genomics in public health: Technology assessment
YouTube video by PAHO TV
162
Ilias Goranitis @iliasgoranitis.bsky.social · 03/04/2025
A must-read: The Cost-Effectiveness of #Genomic_Medicine in #Cancer Control: A Systematic Literature Review link.springer.com/article/10.1... Grateful to the @who.int and Cancer Australia for their support.
link.springer.com
The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review - Applied Health Economics and Health Policy
Background and Objective Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are d...
053
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 24/03/2025
As @ausgenomics.bsky.social comes to an end: what have we learned? 🇦🇺🧬 @naturemedicine.bsky.social 👉 rdcu.be/eeuAN Change is hard! Key for success: working across disciplines; jurisdictions; and all leadership levels🏆 @stephaniebest.bsky.social @iliasgoranitis.bsky.social @andrewmallett8.bsky.social
rdcu.be
Using implementation science to navigate the complexity of integrating genomics into healthcare
Nature Medicine - Australian Genomics led a country-level, longitudinal project to deliver and evaluate the impact of genomics in routine healthcare.
21811
Reposted by Ilias Goranitis
IHEA Econ-Omics SIG @ihea-econ-omics.bsky.social · 18/03/2025
(1/4) Attention Early Career Researchers (ECRs)! We are still collecting expressions of interest for our ECR ‘Preprint Club’ series for 2025. #IHEA #healtheconomics #genomics #precisionmedicine
144
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 06/02/2025
What happens when #genomic testing is funded?🧬 👉 rdcu.be/d8MSL Last 10yrs 🇦🇺: Many tests approved as evidence grows ✅ BUT testing volumes low AND inequitable access Budget impact of #genomics minor: AU$3Mpa or <0.01% of all health expenditure 💰 @ausgenomics.bsky.social @iliasgoranitis.bsky.social
rdcu.be
Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023
European Journal of Human Genetics - Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023
0137
Ilias Goranitis @iliasgoranitis.bsky.social · 06/02/2025
New paper in the European Journal of Human Genetics: Utilisation of subsidised genetic and genomic testing in Australia during 2014–2023 www.nature.com/articles/s41...
nature.com
Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023 - European Journal of Human Genetics
European Journal of Human Genetics - Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023
060
Ilias Goranitis @iliasgoranitis.bsky.social · 05/02/2025
@CancerAustralia has now launched the National Framework for Genomics in Cancer Control. www.canceraustralia.gov.au/key-initiati... It was an honor to lead the #healtheconomics component of the evidence review that informed the development of this framework. Access it through link ⬇️
canceraustralia.gov.au
011
Reposted by Ilias Goranitis
Zornitza Stark @zornitza.bsky.social · 13/01/2025
How do we measure the value of #genomics for #policy decisions? Check out our new GUV scale! 👉 www.valueinhealthjournal.com/article/S109... 👏 great collaboration @iliasgoranitis.bsky.social @andrewmallett8.bsky.social @stephaniebest.bsky.social @zoefehlberg.bsky.social @ausgenomics.bsky.social
valueinhealthjournal.com
A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale
The multifaceted ways in which genomics can be valuable to clinicians, patients, families, and society are important for informing prioritization decisions by policy makers. This study aims to develop...
0196
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
We further map genomic utility evidence from different publicly funded rare disease genomic tests in Australia onto the GUV scale to indicate acceptable #thresholds of #genomic_utility to support prioritization decisions. Read more here doi.org/10.1016/j.jv...
doi.org
Redirecting
010
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
How the GUV scale can be used to support policy decisions is illustrated through a stylized example.
110
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
The scale can be used by researchers in rare disease genomics to design evaluations that capture the key outcomes of genomics & by health technology assessment (HTA) bodies to support policy decisions based on standardized and quantifiable evidence of genomic utility.
120
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
Using @1OOOminds, we performed a multicriteria decision analysis #MCDA with experts involved in policy, clinical, research, and consumer advocacy leadership to enable the cumulative and preference-based scoring of genomic utility on a 0 to 100 scale.
110
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
Our work, published in #ValueinHealth @ISPORJournals, now enables consistency in reporting and benchmarking of different genomic test indications, facilitating evidence-based research and policy decisions.
110
Ilias Goranitis @iliasgoranitis.bsky.social · 13/01/2025
GUV-scale New way to measure & score genomic utility on a 0-100% scale based on 5 policy priority indicators (clinical, diagnostic, economic, societal, and family utility) doi.org/10.1016/j.jv... @zornitza.bsky.social @stephaniebest.bsky.social @andrewmallett8.bsky.social @ausgenomics.bsky.social
doi.org
Redirecting
193
Ilias Goranitis @iliasgoranitis.bsky.social · 16/12/2024
New role within our Economics of Genomics & Precision Medicine Unit - Applications deadline Jan 20 #healtheconomics jobs.unimelb.edu.au/caw/en/job/9...
jobs.unimelb.edu.au
Details : Research Assistant / Research Fellow, Health Economics : The University of Melbourne
Careers at The University of Melbourne
041
Ilias Goranitis @iliasgoranitis.bsky.social · 02/12/2024
Testament to the quality of the work we did with Australian Genomics and the hard work of everyone in my Economics of Genomics and Precision Medicine Unit and Australian Genomics teams!
010
Ilias Goranitis @iliasgoranitis.bsky.social · 02/12/2024
Honoured to receive a Dame Kate Campbell Fellowship and join excellent colleagues in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne who have inspired me with their work over the years!
140
Ilias Goranitis @iliasgoranitis.bsky.social · 02/12/2024
Drinking coffee now from my not so secret Santa gift
000
Ilias Goranitis @iliasgoranitis.bsky.social · 01/12/2024
An important step towards the economic evaluation of #FunctionalGenomics! A #MicroCosting of mass-spectrometry based quantitative #Proteomics url.au.m.mimecastprotect.com/s/TeIxCxnMJ5... @ausgenomics.bsky.social
url.au.m.mimecastprotect.com
A micro-costing study of mass-spectrometry based quantitative proteomics testing applied to the diagnostic pipeline of mitochondrial and other rare disorders
032
Ilias Goranitis @iliasgoranitis.bsky.social · 29/11/2024
Economics of Genomics and Precision Medicine Unit Strategy Day reflections and fun - So proud of the personal & professional qualities of my team #HealthEconomics #Genomics
130
Reposted by Ilias Goranitis
Australian Genomics @ausgenomics.bsky.social · 18/11/2024
On Friday the Australian Government made an important announcement about the new #GenomicsAustralia, a national body that will provide leadership, coordination and expertise so all Australians can reap the benefits of cutting-edge genomic research and technologies. www.health.gov.au/ministers/th...
health.gov.au
13610
Reposted by Ilias Goranitis
IHEA Econ-Omics SIG @ihea-econ-omics.bsky.social · 20/11/2024
Meet our team! @jbuchanan-ox.bsky.social, Ilias Goranitis, and Deirdre Weymann are the founders and lead conveners of the International Health Economics Association Genomics & Precision Medicine Special Interest Group (i.e., the #IHEA Econ-Omics SIG). #healtheconomics #genomics #precisionmedicine
162